RDF Media Group
SPECULATIVE BUYRDF Media’s fortunes have faltered since the BBC’s and ITV’s suspension of business with the TV production group, following last year’s controversy surrounding the editing of a clip of the Queen, which forced the resignation of chief creative director Stephen Lambert.
Results for the year to January, reflecting a turbulent year, revealed a reduction in pre-tax profits to £2m (2007: £6.2m), resulting in a dividend cut to 0.5p (2007: 3p). Planned investments that ‘ran ahead of lower than anticipated revenues’ in the UK production division resulted in a £5.8m increase in overheads to £26m and a sharp rise in year-end debt to £13.7m (2007: £0.2m).
However, the diversified group still achieved 21.5% growth in revenues to £120.6m, with the US division performing strongly, as did the intellectual property division, whose turnover grew by 147% to £9.2m.
While the company will not comment on talks regarding a cash offer to take the company private (by chief executive David Frank and largest shareholder John de Mol, of Endemol fame), broker Altium believes a formal bid will emerge.
Setting a 150p price target for RDF, Altium forecasts growth in revenues for 2009 to £128m, although earnings should reduce to 10.5p (2007: 14.8p) due to an increase in the number of shares in issue following the exercising of options. Based on those estimates, RDF trades on a forward multiple of just 12.1 and should offer a degree of bid excitement. Speculative buy.
Growth Company Investor subscribers have full access to all our AIM and small-cap share recommendations. To subscribe today with a half-price offer, and gain immediate access to all the recommendations, click here.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £53.27m
PE Forecast: 12.1
Share price: 127.5p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
